Patient characteristics
Characteristic . | Value . |
|---|---|
| Sex, n, M/F | 78/46 |
| Median age at transplantation, y (range) | 29 (1-59) |
| Median interval from diagnosis to transplantation, d (range) | 470 (183-2329) |
| Histology, n | |
| Low-grade | 10 |
| Follicular lymphoma | 9 |
| Small lymphocytic lymphoma | 1 |
| Intermediate-grade | 42 |
| Peripheral T-cell lymphoma, unspecified | 14 |
| NK-cell lymphoma | 12 |
| Anaplastic large cell lymphoma | 6 |
| Diffuse large B-cell lymphoma | 5 |
| Angioimmunoblastic lymphoma | 1 |
| Mantle cell lymphoma | 1 |
| High-grade | 60 |
| Lymphoblastic lymphoma | 39 |
| Adult T-cell leukemia/lymphoma | 15 |
| Burkitt lymphoma | 5 |
| Unclassified | 12 |
| Previous history of HDT/ASCT, n | |
| Yes | 18 |
| No | 83 |
| ND | 23 |
| Disease status at transplantation, n | |
| CR | 60 (CR1 19, CR2 18, CR3 5, CR4 1) |
| Non-CR | 60 |
| ND | 4 |
| Chemosensitivity at transplantation, n | |
| Sensitive | 76 |
| Resistant | 33 |
| ND | 15 |
| Conditioning regimen, n | |
| TBI-containing regimen | 111 |
| Non-TBI regimen | 13 |
| GVHD prophylaxis, n | |
| CsA ± MTX ± steroid | 76 |
| TCR ± MTX ± steroid | 44 |
| CsA + TCR ± MTX ± steroid | 3 |
| MTX alone | 1 |
Characteristic . | Value . |
|---|---|
| Sex, n, M/F | 78/46 |
| Median age at transplantation, y (range) | 29 (1-59) |
| Median interval from diagnosis to transplantation, d (range) | 470 (183-2329) |
| Histology, n | |
| Low-grade | 10 |
| Follicular lymphoma | 9 |
| Small lymphocytic lymphoma | 1 |
| Intermediate-grade | 42 |
| Peripheral T-cell lymphoma, unspecified | 14 |
| NK-cell lymphoma | 12 |
| Anaplastic large cell lymphoma | 6 |
| Diffuse large B-cell lymphoma | 5 |
| Angioimmunoblastic lymphoma | 1 |
| Mantle cell lymphoma | 1 |
| High-grade | 60 |
| Lymphoblastic lymphoma | 39 |
| Adult T-cell leukemia/lymphoma | 15 |
| Burkitt lymphoma | 5 |
| Unclassified | 12 |
| Previous history of HDT/ASCT, n | |
| Yes | 18 |
| No | 83 |
| ND | 23 |
| Disease status at transplantation, n | |
| CR | 60 (CR1 19, CR2 18, CR3 5, CR4 1) |
| Non-CR | 60 |
| ND | 4 |
| Chemosensitivity at transplantation, n | |
| Sensitive | 76 |
| Resistant | 33 |
| ND | 15 |
| Conditioning regimen, n | |
| TBI-containing regimen | 111 |
| Non-TBI regimen | 13 |
| GVHD prophylaxis, n | |
| CsA ± MTX ± steroid | 76 |
| TCR ± MTX ± steroid | 44 |
| CsA + TCR ± MTX ± steroid | 3 |
| MTX alone | 1 |
HDT/ASCT indicates high-dose therapy and autologous stem cell transplantation; CR, complete remission (CR1, CR2, CR3, CR4; the first, second, third, and fourth CR, respectively); ND, not described; TBI, total body irradiation; GVHD, graft-versus-host disease; CsA, cyclosporine A; MTX, methotrexate; TCR, tacrolimus.